Optimizing Patient Access to CDK 4/6 Inhibitors for the Treatment of HR+/HER2- Metastatic Breast Cancer:
Payer Implications for the Oncology Provider to Consider

• Release Date: June 7, 2022
• Expiration Date: December 31, 2023
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

Expert Faculty Author:

Jeffrey Dunn, PharmD, MBA Chief Clinical Officer Cooperative Benefits Group Click here for biography Jane Lowe Meisel, MD Associate Professor of Hematology and Medical Oncology Associate Vice Chair of Faculty Development and Promotions Winship Cancer Institute at Emory University Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, care managers, registered nurses, and other managed care and payer organization professionals.

Statement of Need/Program Overview
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common breast cancer subtype. Although endocrine therapy is usually effective initially, approximately 50% of HR+ patients develop resistance to this intervention, ultimately leading to disease recurrence. For patients with HR+/HER2-metastatic breast cancer (mBC), the addition of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors to ET limits estrogen-induced tumor cell proliferation, minimizes endocrine resistance, and leads to greater progression free survival (PFS) vs. ET alone. This activity will help enable managed care and payer professionals to better understand the relevant findings from randomized clinical trials and real-world evidence of CDK 4/6 inhibitors to accurately interpret current evidence to inform development of policies and management procedures that appropriately align patients and treatment in order to enhance access to therapy, augment delivery of high-quality care, and improve treatment outcomes.

Educational Objectives
After completing this activity, the participant should be better able to:

• Review recent clinical trial data and real-world evidence relevant to the use of CDK 4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
• Evaluate benefit design strategies that provide equal access to CDK 4/6i therapy to all appropriate HR+/HER2- mBC patients
• Discuss best practices that ensure delivery of high quality, evidence-based, multidisciplinary care similar to that delivered by academic or National Cancer Institute-designated cancer centers

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-245-H01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

• Complete the evaluation form
• For ACCME and ANCC accreditation, a CE certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.